The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes-in vitro study

Clinical Oral Investigations

Volumn 16, Issue 1, 2012, Pages 87-93

  Pabst, Andreas M ^a   Ziebart, Thomas ^a   Koch, Felix P ^a   Taylor, Katherine Y ^a   Al Nawas, Bilal ^a   Walter, Christian ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Bisphosphonate; Etiology; Keratinocytes; Osteonecrosis of the jaws

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CALCEIN; CLODRONIC ACID; COLORING AGENT; DIAGNOSTIC AGENT; FLUORESCEIN DERIVATIVE; FLUORESCENT DYE; IBANDRONIC ACID; IMIDAZOLE DERIVATIVE; PAMIDRONIC ACID; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; CELL LINE; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CULTURE TECHNIQUE; CYTOLOGY; DRUG EFFECT; HUMAN; KERATINOCYTE; MOUTH MUCOSA; NICK END LABELING;

APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CELL CULTURE TECHNIQUES; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CLODRONIC ACID; COLORING AGENTS; DIPHOSPHONATES; FLUORESCEINS; FLUORESCENT DYES; HUMANS; IMIDAZOLES; IN SITU NICK-END LABELING; KERATINOCYTES; MOUTH MUCOSA; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84855979403     PISSN: 14326981     EISSN: 14363771     Source Type: Journal    
DOI: 10.1007/s00784-010-0507-6     Document Type: Article

References (34)

1. Diel IJ, Bergner R, Grötz KA (2007) Adverse effects of bisphosphonates: current issues. J Support Oncol 5: 475-482.
2. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of jaws: a growing epidemic. J Oral Maxillofac Surg 61: 1115-1117.
3. Walter C, Grötz KA, Kunkel M, Al-Nawas B (2007) Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 15: 197-202.
4. Ruggiero SL, Dodson TB, Asseal LA, Landesberg R, Marx RE, Mehrotra B (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 67: 2-12.
5. Allan MR, Burr DB (2009) The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67: 61-70.
6. Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2009) Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 14: 35-41.
7. Walter C, Pabst A, Ziebart T, Klein MO, Al-Nawas B (2010) Bisphosphonates influence migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro. Oral Dis (in press).
8. Henry D, von Moos R, Vadhan-Raj S, Hunfria V, Spencer A, Hirsh V, Wang J, Jun S, Dansey R, Yeh H (2009) A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Presented at the Joint ECCO 15-34th ESMO Multidisciplinary Congress, Berlin, 20-24 Sept 2009.
9. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (in press).
10. Neville-Webbe HL, Coleman RE (2010) Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone diseases. Eur J Cancer 46(7): 1211-1222.
11. Taylor KH, Middlefell LS, Mizen KD (2010) Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 48: 221-223.
12. Santini D, Vincenzi B, Avvisati G et al (2002) Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8: 1080-1084.
13. Ziebart T, Pabst A, Klein MO, Kammerer P, Gauss L, Brullamnn D, Al-Nawas B, Walter C (2009) Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig (in press).
14. Reid IR, Bolland MJ, Grey AB (2007) Is bisphosphonate-associated osteonecrosis of the jaw caused by soft-tissue toxicity? Bone 41: 318-320.
15. Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W (2008) Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54: 1066-1107.
16. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42: 1228-1236.
17. Moreira MS, Katamaya E, Bombana AC, Marques MM (2005) Cytotoxicity analysis of alendronate on cultured endothelial cells and subcutaneous tissue. A pilot study. Dent Traumatol 21: 329-335.
18. Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF (2009) Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 144: 667-676.
19. Scheper M, Chaisuparat R, Cullen K, Meiller T (2010) A novel-soft tissue in vitro model for bisphosphonate-associated osteonecrosis. Fibrogenesis Tissue Repair 3: 6.
20. Felix R, Guenther HL, Fleisch H (1984) The subcellular distribution of [14 C]dichloromethylenebisphosphonate and [14 C]1-hydroxyethylidene-1, 1- bisphosphonate in cultured calvaria cells. Calcif Tissue Int 36: 108-113.
21. Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC (1990) Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 85: 456-461.
22. Fromigue O, Body JJ (2002) Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Investig 25: 539-546.
23. Xiong Y, Yang HJ, Feng J, Shi ZL, Wu LD (2009) Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells. J Int Med Res 37: 407-416.
24. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, Garrett-Sinha L, Raghavan S (2008) Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66: 839-847.
25. Reszka AA, Halasy-Nagy J, Rodan GA (2001) Nitrogen bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 59: 193-202.
26. Twiss IM, de Water R, den Hartigh J, Sparidans R, Ramp-Koopmanschap W, Brill H, Wijdeveld M, Vermeij P (1994) Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. J Pharm Sci 83: 699-703.
27. De Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335: 1016-1021.
28. Gonzalez-Moles MA, Bagan-Sebastian JV (2000) Alendronate-related oral mucosa ulcerations. J Oral Pathol Med 29: 514-518.
29. Rubegni P, Fimiani M (2006) Images in clinical medicine. Bisphosphonate-associated contact stomatitis. N Engl J Med 355: e25.
30. Walker K, Olson MF (2005) Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr Opin Genet Dev 15: 62-68.
31. Suri S, Monkkonen J, Taskinen M, Peseson J, Blank MA, Phipps RJ, Rogers MJ (2001) Nitrogen-containing bisphosphoantes induce apoptosis of Caco-2 cells in vitro by inhibition the mevalonate pathway: a model of bisphosphoante-induced gastrointestinal toxicity. Bone 29: 336-343.
32. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62: 527-534.
33. Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65: 2397-2410.
34. Montazeri AH, Erskine JG, McQuaker IG (2007) Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. Eur J Haematol 79: 69-71.